Diabetes

The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

A new study has found increased risks for liver, pancreatic, and bowel cancers following a new diagnosis of type 2 diabetes—but not all obesity-related cancers show a link.

Rural health sign | Image credit: BJP7images - stock.adobe.com
FQHCs Show Low Engagement in Hypertension, Diabetes Trials

April 15th 2025

AI representation of housing stability | Image credit: GoldPumaze - stock.adobe.com
Housing Instability Linked to Worse Type 2 Diabetes Outcomes

April 14th 2025

Diabetes concept | Image credit: Sherry Young - stock.adobe.com
GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

April 9th 2025

AJMC
The Role of Advanced Technologies in Improving Diabetes Outcomes

April 7th 2025

More News

Gavel and money | Image credit: BillionPhotos.com - stock.adobe.com
September 20th 2024

FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs

Skylar Jeremias
The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin costs for patients, prompting renewed calls for PBM reform.
AJMC
September 5th 2024

Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes

Keith A. Betts, PhD Nikolaus G. Oberprieler, PhD, MSc, MBA Aozhou Wu, PhD Glen James, PhD Scott Beeman, PharmD Alain Gay, MD Xuanhao He, PhD David Vizcaya, PhD, MPH
This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.
Hot dogs with ketchup and mustard | Image credit: Mediteraneo – stock.adobe.com
September 4th 2024

Meat Consumption and Increased Diabetes Risk: Building on the Current Evidence Base

Hayden E. Klein
New findings add to the relationship between red meat and processed meat consumption and the risk of type 2 diabetes.
CGM | Image credit: Andrey Popov – stock.adobe.com
Published: August 27th 2024 | Updated: August 27th 2024

FDA Expands Omnipod 5 AID System Label to Treat Type 2 Diabetes

Hayden E. Klein
The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections.
Red, yellow, and green trees reflecting memory loss or recovery | Image credit: freshidea – stock.adobe.com
August 27th 2024

SGLT2 Inhibitors, GLP-1 Agonists Similarly Reduce Dementia Risk for Patients With Diabetes

Hayden E. Klein
New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes.
Jose A. Martinez, MD
August 20th 2024

Choosing the Right Treatment Path for Diabetic Macular Edema

Hayden E. Klein
Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach.
Using Telemedicine to Expand Diabetic Retinopathy Screening
August 16th 2024

Using Telemedicine to Expand Diabetic Retinopathy Screening

Hayden E. Klein
Despite guidelines recommending annual screenings, nearly half of patients with diabetes miss critical eye exams, explains Jose A. Martinez, MD, president and retina specialist at Austin Retina Associates.
AJMC
August 7th 2024

Adherence Patterns 1 Year After Initiation of SGLT2 Inhibitors: Results of a National Cohort Study

Hsiao-Ching Huang, PhD Daniel R. Touchette, PharmD, MA Mina Tadrous, PhD Glen T. Schumock, PharmD, PhD, MBA Saria Awadalla, PhD Todd A. Lee, PhD
This article describes the trajectory of adherence patterns among users of sodium-glucose cotransporter 2 (SGLT2) inhibitors. The authors found that baseline factors were unable to predict the adherence trajectory groups.
What We’re Reading: Ozempic Linked to Lower Tobacco-Related Health Care Use; Medical Debt Relief Plan in North Carolina; Nearly 1 in 4 US Adults Face Mental Health Care Barrier
July 30th 2024

What We’re Reading: Ozempic and Smoking Cessation; North Carolina’s Medical Debt Relief Plan; Mental Health Care Barriers

AJMC Staff
Smokers with diabetes on Ozempic are less likely to receive smoking cessation interventions; initiative incentivizes hospitals to eliminate medical debt for low- and middle-income patients; high costs prevent mental health treatment.
Older woman sleeping with clock on nightstand | Image credit: Pixel-Shot – stock.adobe.com
July 17th 2024

Inconsistent Sleep May Heighten Older Adults’ Risk of Diabetes

Hayden E. Klein
Older adults with the most irregular sleep durations demonstrated a 34% higher risk of developing type 2 diabetes compared with those with the most regular sleep.
What We’re Reading: Change Cyberattack Exposes Personal Data; Ozempic May Reduce Dementia Risk; Rural Hospitals Shutdown
July 15th 2024

What We’re Reading: Cyberattack Exposes Personal Data; Semaglutide May Reduce Dementia Risk; Rural Hospitals Shutdown

AJMC Staff
Up to one-third of Americans have been affected by data stolen through the Change Healthcare cyberattack; research highlights potential cognitive and psychiatric benefits of semaglutide; over 40 Iowa hospitals have ended their labor and delivery services.
what we're reading logo
July 10th 2024

What We’re Reading: CMS Dementia Care Program; Physician Burnout Drops; Impact of GLP-1 Shortages

AJMC Staff
CMS recently launched a voluntary, nationwide dementia care program; the number of physicians who reported at least 1 symptom of burnout has dropped below 50% for the first time since the onset of the COVID-19 pandemic; diabetes drugs have all been in short supply over the last 18 months, partly due to people using them off label for weight loss.
Doctor and patient discussing treatment plan | Image credit: Halfpoint – stock.adobe.com
July 5th 2024

GLP-1 Agonists May Reduce Cancer Risk for Patients With Diabetes

Hayden E. Klein
Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did.
Ian Neeland, MD
June 21st 2024

Obesity Management in 2024: A Look at the CINEMA Program’s Growth and Impact

Hayden E. Klein
The University Hospitals CINEMA program aims to address issues and narrow gaps in obesity management, with a focus on meeting patients where they are and providing them tools for success, says Ian Neeland, MD.
Robert Lustig, MD, MSL
June 21st 2024

Dr Robert Lustig on Pediatric Metabolic Health: “Sugar Is the Alcohol of the Child”

Hayden E. Klein
Robert Lustig, MD, MSL, explains how the US health care industry needs to shift from measuring body mass index and obesity to measuring cardiometabolic health, which affects 93% of Americans, including children.
What We’re Reading: Change Healthcare Warns of Massive Data Breach; Early Gestational Diabetes Screening; Bird Flu Testing Delays
June 21st 2024

What We’re Reading: Change Healthcare to Send Data Breach Warnings; Early Gestational Diabetes Screening; Bird Flu Testing Delays

AJMC Staff
Change Healthcare will begin notifying individuals whose data may have been exposed when hackers disrupted the claims processing system; experts advocate for early diagnosis of gestational diabetes to mitigate risks for both mother and child; researchers worry that the slow rollout of bird flu tests may hinder outbreak detection and response.
Ozempic | Image credit: mbruxelle – stock.adobe.com
June 20th 2024

WHO Issues Warning for Fake Semaglutide

Hayden E. Klein
Taking falsified semaglutide (Ozempic; Novo Nordisk) can lead to ineffective treatment due to incorrect dosing, contamination, and the use of unknown ingredients, the World Health Organization (WHO) is warning.
Age, Insurance Play Major Roles in CGM Use, Says Dr Chase Hendrickson
June 18th 2024

Age, Insurance Play Major Roles in CGM Use, Says Dr Chase Hendrickson

Hayden E. Klein
Patients with diabetes who have private insurance are more likely to be prescribed a continuous glucose monitor (CGM) compared with those with government insurance, says Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center.
FDA | Image credit: Araki Illustrations – stock.adobe.com
June 13th 2024

FDA Approves Dapagliflozin for Children With Type 2 Diabetes

Hayden E. Klein
Children aged 10 years and older with type 2 diabetes can now improve their glycemic control with a drug previously only approved for adults.
Semaglutide injections | Image credit: Patrick Bay Damsted – stock.adobe.com
May 24th 2024

Semaglutide Lowers Risk of Major Kidney Outcomes, Cardiovascular Events, Death in Patients With Diabetes and CKD

Hayden E. Klein
Patients who took the weekly glucagon-like peptide 1 (GLP-1) receptor agonist were 21% less likely to experience major kidney disease events and 29% less likely to die due to cardiovascular causes.
Supply of tirzepatide | Image credit: MKPhoto – stock.adobe.com
May 16th 2024

Most Insured Adults Still Have to Pay at Least Part of the Cost of GLP-1 Drugs

Hayden E. Klein
Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and opinions on Medicare coverage of glucagon-like peptide-1 (GLP-1) drugs.
Art Masturzo, MD, MBA
May 6th 2024

Dr Arti Masturzo Gives an In-Depth Look at CCS Survey Results Showing Misconceptions Around Diabetes Management

Hayden E. Klein
Survey results from more than 1500 patients with diabetes revealed that 57% believed glucagon-like peptide-1 (GLP-1) weight loss drugs alone could be a "silver bullet" for managing their health goals.
Joanne Mizell
May 1st 2024

Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease

Giuliana Grossi
Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Continuous glucose monitor | Image credit: habrovich – stock.adobe.com
April 17th 2024

Beyond Insulin: The Impact of Next-Generation Diabetes Technology

Hayden E. Klein Laura Joszt, MA
Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
April 15th 2024

Dr Kevin Malloy Discusses the Evolution of GLP-1 Receptor Agonists

Kyle Munz
Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES, Cleveland Clinic, discusses how GLP-1 receptor agonists have evolved in the treatment landscape of diabetes and obesity at an Institute for Value-Based Medicine® event hosted in conjunction with Cleveland Clinic.
AJMC
April 1st 2024

Medication Persistence and Its Impact on Type 2 Diabetes

Jee H. Choe, MS Si Xuan, PhD Antony Goldenberg, PharmD Jacqueline Matian, PharmD Jeff McCombs, PhD Rory E. Kim, PharmD, MACM, BCACP
Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs.
Woman having eye exam by optometrist | Image Credit: © Nicholas Felix/peopleimages.com - stock.adobe.com
March 19th 2024

Breaking Barriers: Partnerships to Improve Diabetic Eye Health in Alabama

Bryan A. Wilson, PhD, MBA Danielle Haney, PhD Risa Reuscher, PharmD David Tabano, PhD Kimberly Jinnett, PhD Ayesha Ahmed, PharmD Andrew Gordon, MD, PhD Anthony Coleman, BS Raelle Wilson, MA Rachel Israel, BS Jenee Williams, MBA Marina Pevzner Hennessy, MS Terri Wiggins, MS Elizabeth J. Pekas, PhD Raveendhara R. Bannuru, MD, PhD
This article reviews barriers to diabetic eye health across Alabama and highlights a partnership with Genentech and the American Diabetes Association to address this issue.
Survey questionnaire | Image credit: Kay Abrahams peopleimages.com – stock.adobe.com
March 8th 2024

CCS Report Reveals Misconceptions Among People Living With Diabetes; Calls for Enhanced Engagement, Education

Hayden E. Klein
A survey of more than 1500 people revealed misconceptions about living with diabetes, particularly regarding the efficacy of GLP-1 weight loss drugs as a standalone solution for managing their health goals.
AJMC
March 8th 2024

Improving Glycemic Control in Diabetes Through Virtual Interdisciplinary Rounds

Abby F. Hoffman, PhD Cindy Leslie Roberson, PharmD Pamela Cohen, BA Victoria Lee Jackson, PharmD John Yeatts, MD Patrick Gregory, PharmD Samantha Wong, MD Susan E. Spratt, MD
Patients with diabetes whose providers received advice from remote, virtual interdisciplinary rounds had a greater 1-year reduction in hemoglobin A1c than comparable patients.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
March 6th 2024

FDA Approves First Over-the-Counter Continuous Glucose Monitor

Hayden E. Klein
Starting summer 2024, individuals across the US will be able to purchase a continuous glucose monitor (CGM) without needing a prescription.
<12345678
...
98>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo